JP2023527926A5 - - Google Patents
Info
- Publication number
- JP2023527926A5 JP2023527926A5 JP2022574537A JP2022574537A JP2023527926A5 JP 2023527926 A5 JP2023527926 A5 JP 2023527926A5 JP 2022574537 A JP2022574537 A JP 2022574537A JP 2022574537 A JP2022574537 A JP 2022574537A JP 2023527926 A5 JP2023527926 A5 JP 2023527926A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody molecule
- therapeutic antibody
- pharmaceutical preparation
- diseases
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20178287.7 | 2020-06-04 | ||
| EP20178287.7A EP3919077A1 (en) | 2020-06-04 | 2020-06-04 | Model for prediction of tolerability issues in connection with intravenous administration of therapeutic antibodies |
| EP21163703 | 2021-03-19 | ||
| EP21163703.8 | 2021-03-19 | ||
| PCT/EP2021/065014 WO2021245238A1 (en) | 2020-06-04 | 2021-06-04 | Improving antibody tolerability associated with intravenous administration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023527926A JP2023527926A (ja) | 2023-06-30 |
| JP2023527926A5 true JP2023527926A5 (cg-RX-API-DMAC10.html) | 2024-05-23 |
Family
ID=76217874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022574537A Pending JP2023527926A (ja) | 2020-06-04 | 2021-06-04 | 静脈内投与と関連する抗体耐容性の改善 |
Country Status (12)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202342057A (zh) * | 2022-02-07 | 2023-11-01 | 美商健生生物科技公司 | 用於減少用ｅｇｆｒ／ｍｅｔ雙特異性抗體治療之患者的輸注相關反應之方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ243706A (en) | 1991-07-25 | 1994-08-26 | Idec Pharma Corp | Recombinant monkey antibodies, pharmaceutical compositions |
| US8187593B2 (en) * | 2002-08-14 | 2012-05-29 | Macrogenics, Inc. | FcγRIIB specific antibodies and methods of use thereof |
| MX2012004406A (es) * | 2009-10-21 | 2012-05-08 | Immunogen Inc | Nuevo regimen de dosificacion y metodo de tratamiento. |
| GB201013989D0 (en) | 2010-08-20 | 2010-10-06 | Univ Southampton | Biological materials and methods of using the same |
| GB2526139A (en) | 2014-05-15 | 2015-11-18 | Biolnvent Internat Ab | Medicaments, uses and methods |
| CN108602889A (zh) * | 2015-12-22 | 2018-09-28 | 瑞泽恩制药公司 | 医治急性成淋巴细胞性白血病的双特异性抗cd20/抗cd3抗体 |
| WO2019081983A1 (en) * | 2017-10-25 | 2019-05-02 | Novartis Ag | CD32B TARGETING ANTIBODIES AND METHODS OF USE |
| JP7800852B2 (ja) | 2018-01-10 | 2026-01-16 | バイオインヴェント インターナショナル アーベー | 抗体の新規組み合わせおよびその使用 |
| EA202190102A1 (ru) | 2018-08-16 | 2021-07-29 | Генмаб А/С | Коньюгаты антител к тканевым факторам с лекарственным средством и их применение в лечении рака |
| ES3009025T3 (en) | 2018-08-31 | 2025-03-25 | Regeneron Pharma | Dosing strategy that mitigates cytokine release syndrome for cd3/cd20 bispecific antibodies |
-
2021
- 2021-06-04 US US18/008,134 patent/US20230322933A1/en active Pending
- 2021-06-04 IL IL298757A patent/IL298757A/en unknown
- 2021-06-04 CA CA3185020A patent/CA3185020A1/en active Pending
- 2021-06-04 WO PCT/EP2021/065005 patent/WO2021245233A1/en not_active Ceased
- 2021-06-04 MX MX2022015229A patent/MX2022015229A/es unknown
- 2021-06-04 JP JP2022574537A patent/JP2023527926A/ja active Pending
- 2021-06-04 AU AU2021286202A patent/AU2021286202A1/en active Pending
- 2021-06-04 EP EP21729338.0A patent/EP4161574A1/en active Pending
- 2021-06-04 KR KR1020237000393A patent/KR20230038180A/ko active Pending
- 2021-06-04 US US18/008,141 patent/US20240301070A1/en active Pending
- 2021-06-04 TW TW110120461A patent/TW202210102A/zh unknown
- 2021-06-04 BR BR112022024745A patent/BR112022024745A2/pt unknown
- 2021-06-04 WO PCT/EP2021/065014 patent/WO2021245238A1/en not_active Ceased
- 2021-06-04 TW TW110120464A patent/TW202210104A/zh unknown
- 2021-06-04 CN CN202180058034.4A patent/CN116322767A/zh active Pending
- 2021-06-04 EP EP21729337.2A patent/EP4161573A1/en active Pending
- 2021-06-04 TW TW110120463A patent/TW202210103A/zh unknown
- 2021-06-04 WO PCT/EP2021/065013 patent/WO2021245237A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024174927A5 (cg-RX-API-DMAC10.html) | ||
| JP2025020134A5 (cg-RX-API-DMAC10.html) | ||
| JP2023166388A5 (cg-RX-API-DMAC10.html) | ||
| AU2014249534B2 (en) | Use of levocetirizine and montelukast in the treatment of vasculitis | |
| JP2016074740A5 (cg-RX-API-DMAC10.html) | ||
| JP2005520778A5 (cg-RX-API-DMAC10.html) | ||
| CN1111414C (zh) | 镁盐或镁配合物的制药用途 | |
| EP4087555A1 (en) | Methods of using andrographolide, oridonin and isoliquiritigenin and derivatives thereof | |
| JP2025148449A5 (cg-RX-API-DMAC10.html) | ||
| IL307751B1 (en) | Treatment of lupus nephritis with anti-type i inf receptor antibody anifrolumab | |
| JP2002530353A5 (cg-RX-API-DMAC10.html) | ||
| KR20120138229A (ko) | 정맥내 투여용 이부프로펜을 이용한 중증 환자의 치료 | |
| JP2024542777A5 (cg-RX-API-DMAC10.html) | ||
| CN115463118A (zh) | 和厚朴酚在制备治疗或预防毛细血管瘤的药物中的用途 | |
| Waymack et al. | A prospective trial of prophylactic intravenous immune globulin for the prevention of infections in severely burned patients | |
| AU706729B2 (en) | Novel indications for the use as medicaments of multipotent parapox immunity inducers from attenuated, non-immunogenic pox viruses or parapox viruses | |
| JP2005529152A5 (cg-RX-API-DMAC10.html) | ||
| US20070122384A1 (en) | Method for treating inflammatory bowel disease | |
| JP2023550043A5 (cg-RX-API-DMAC10.html) | ||
| JP2000186040A (ja) | 抗ｈｉｖ感染症剤 | |
| CN108014337B (zh) | 一种用于治疗眼自身免疫性葡萄膜炎的药物组合物 | |
| WO2000038682A1 (en) | Anti-hiv infection agents and method for treating hiv infection | |
| JP2001089370A (ja) | 肝疾患治療剤 | |
| CN117243946A (zh) | 瑞香素及包含其的组合物在制备治疗心肌炎药物中的应用 | |
| WO2023245470A1 (zh) | Mdp类似物在制备用于治疗炎症性肠病的药物中的用途 |